DTC02 - correct. This is the biggest trial ever conducted on...

DTC02 - correct. This is the biggest trial ever conducted on Liver cancer for this type of treatment. Oncologists will be very interested in the data, especially the overall PFS value.

The PFS for liver is also most interesting. We are of the view that SRX needed about 3 months additional time to trigger this results. I'm not so sure if 3 mths is about right or not, but assuming it is then any results significantly above the 3 month marker would be very well received by the medcos.

As for the overall PFS, assuming the 3 month marker was required to claim a tick, then depending on the variance to this marker will also have an impact. If the value for OPFS is under a month, or worse still less than the control arm then questions will be asked. If the result is close to the 3 month marker then medcos will be more open to using SIRT in 1st line, IMO.

As an oncologist, one may presume, it is better to know where a treatment gives the best result and where it does not. A move to 1st line for Liver ONLY sufferers would be a good result to start with. Hopefully we can get that far, and then the marketing slog begins.